Back to Search
Start Over
The anti-fibrotic actions of relaxin are mediated through AT 2 R-associated protein phosphatases via RXFP1-AT 2 R functional crosstalk in human cardiac myofibroblasts.
- Source :
-
FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2020 Jun; Vol. 34 (6), pp. 8217-8233. Date of Electronic Publication: 2020 Apr 16. - Publication Year :
- 2020
-
Abstract
- Fibrosis is a hallmark of several cardiovascular diseases. The relaxin family peptide receptor 1 (RXFP1) agonist, relaxin, has rapidly occurring anti-fibrotic actions which are mediated through RXFP1 and angiotensin II receptor crosstalk on renal and cardiac myofibroblasts. Here, we investigated whether this would allow relaxin to indirectly activate angiotensin II type 2 receptor (AT <subscript>2</subscript> R)-specific signal transduction in primary human cardiac myofibroblasts (HCMFs). The anti-fibrotic effects of recombinant human relaxin (RLX; 16.8 nM) or the AT <subscript>2</subscript> R-agonist, Compound 21 (C21; 1 μM), were evaluated in TGF-β1-stimulated HCMFs, in the absence or presence of an RXFP1 antagonist (1 μM) or AT <subscript>2</subscript> R antagonist (0.1 μM) to confirm RXFP1-AT <subscript>2</subscript> R crosstalk. Competition binding for RXFP1 was determined. Western blotting was performed to determine which AT <subscript>2</subscript> R-specific protein phosphatases were expressed by HCMFs; then, the anti-fibrotic effects of RLX and/or C21 were evaluated in the absence or presence of pharmacological inhibition (NSC95397 (1 μM) for MKP-1; okadaic acid (10 nM) for PP2A) or siRNA-knockdown of these phosphatases after 72 hours. The RLX- or C21-induced increase in ERK1/2 and nNOS phosphorylation, and decrease in α-SMA (myofibroblast differentiation) and collagen-I expression by HCMFs was abrogated by pharmacological blockade of RXFP1 or the AT <subscript>2</subscript> R, confirming RXFP1-AT <subscript>2</subscript> R crosstalk in these cells. HCMFs were found to express AT <subscript>2</subscript> R-dependent MKP-1 and PP2A phosphatases, while pharmacological blockade or siRNA-knockdown of either phosphatase also abolished RLX and/or C21 signal transduction in HCMFs (all P < .05 vs RLX or C21 alone). These findings demonstrated that RLX can indirectly activate AT <subscript>2</subscript> R-dependent phosphatase activity in HCMFs by signaling through RXFP1-AT <subscript>2</subscript> R crosstalk, which have important therapeutic implications for its anti-fibrotic actions.<br /> (© 2020 Federation of American Societies for Experimental Biology.)
- Subjects :
- Cell Differentiation drug effects
Cells, Cultured
Human Umbilical Vein Endothelial Cells
Humans
Nitric Oxide Synthase Type I metabolism
Phosphoprotein Phosphatases metabolism
Signal Transduction drug effects
Transforming Growth Factor beta1 metabolism
Fibrosis drug therapy
Fibrosis metabolism
Heart drug effects
Myofibroblasts drug effects
Myofibroblasts metabolism
Receptor, Angiotensin, Type 2 metabolism
Receptors, G-Protein-Coupled metabolism
Receptors, Peptide metabolism
Relaxin pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1530-6860
- Volume :
- 34
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- Publication Type :
- Academic Journal
- Accession number :
- 32297670
- Full Text :
- https://doi.org/10.1096/fj.201902506R